Daré Bioscience, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing. Daré is a women’s-health biopharmaceutical company with one operating segment. Its portfolio is primarily investigational; XACIATO is its only FDA-approved product and is licensed to Organon.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $2.81 million | $10.00 million |
| Operating expenses | $33.75 million | $41.39 million |
| Loss from operations | $(30.94) million | $(31.39) million |
| Net loss | $(30.16) million | $(30.95) million |
| Net loss per share, basic and diluted | $(0.35) | $(0.37) |
| Net cash used in operating activities | $(38.86) million | $(18.09) million |
- Revenue consisted primarily of Organon payments: $1.0 million license-fee revenue, a $1.8 million first-commercial-sale milestone and approximately $7,900 in royalties. The 2022 comparison included a $10.0 million upfront license payment.
- R&D expense fell 28% to $21.54 million, mainly reflecting lower Sildenafil Cream and Ovaprene development and manufacturing costs. G&A rose 8% to $12.11 million. Grant funding reduced R&D expense by $9.3 million in 2023, versus $5.6 million in 2022.
- At year-end, cash and cash equivalents were $10.48 million, total assets $21.28 million, total liabilities $26.33 million, working capital deficit approximately $2.9 million and stockholders’ deficit $5.05 million. Of year-end cash, $13.7 million was reported as deferred grant funding liability; grant funds are generally restricted to specified development costs, so reported cash is not fully available for general operations.
- Cash decreased by $23.86 million during 2023. Financing provided $15.64 million, including equity proceeds, warrant exercises and $4.72 million net proceeds from the sale of future XACIATO royalties. Investing used $0.63 million.
- The royalty financing produced $5.0 million upfront cash. Daré recorded a $3.91 million net liability at year-end after issuance costs and warrant allocation; the estimated effective annual interest rate was 22.48%. Daré must remit specified portions of XACIATO royalties and milestones until the investor receives a 12% return. This is a royalty-backed financing obligation, not evidence of conventional bank debt.
- Management said additional capital was needed to fund operations into the third quarter of 2024 and meet obligations. The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern; the financial statements contain no adjustments for a possible failure to continue.
Business, developments and outlook
- Organon began U.S. marketing of XACIATO in Q4 2023 and assumed the NDA, manufacturing, regulatory and compliance responsibilities in December. Daré’s future XACIATO income depends on Organon’s sales and consists of royalties and potential milestones. Daré’s royalty-financing agreement assigns a substantial share of those receipts to the financier until the contractual return threshold is met.
- Ovaprene’s pivotal Phase 3 contraceptive study began in December 2023. It aims for approximately 250 participants to complete about 12 months of use. Daré has paid $5.0 million of its $5.5 million CRADA contribution; the remaining $0.5 million was expected in Q3 2024. Bayer’s U.S. commercialization license is not yet effective: Bayer may elect to activate it by paying $20 million, at its discretion.
- Sildenafil Cream’s Phase 2b RESPOND study did not meet its co-primary or secondary endpoints. The company cited improvements in exploratory endpoints and post-hoc subgroup analyses. In January 2024, Daré reported FDA alignment at an end-of-Phase-2 meeting on key elements of a proposed Phase 3 program; additional FDA feedback on endpoints and safety requirements was pending.
- DARE-HRT1 completed a Phase 1/2 study; DARE-VVA1 received FDA IND clearance; and DARE-PDM1 reported positive topline Phase 1 findings. The filing says planned further studies for several candidates, including DARE-HRT1, DARE-VVA1 and DARE-CIN, depend on securing additional capital.
- Management expects continued losses and negative operating cash flow. Until additional funding is secured, it plans to prioritize Ovaprene and Sildenafil Cream, while grant funding supports DARE-LARC1 preclinical work. No quantified revenue or earnings guidance is provided.
Material changes, risks and unusual items
- Total revenue fell 72%, largely because 2022 included the $10.0 million Organon upfront payment. Net loss improved slightly, but operating cash use more than doubled, affected in part by working-capital movements, including lower accrued expenses and deferred grant funding.
- Daré relies on external capital, grants, collaborators and third-party manufacturers; it has no in-house manufacturing or commercial sales infrastructure. Management warns that inability to raise funds could force delays, program reductions, restructuring or cessation of operations.
- Nasdaq had notified Daré of noncompliance with the $1.00 minimum bid-price requirement. The company received a temporary exception through July 15, 2024, subject to conditions including a reverse stock split if necessary; failure to meet the terms could result in delisting. The filing also states that year-end equity and recent net income did not meet certain other Nasdaq continued-listing standards.
- Potential dilution is significant: at December 31, 2023, approximately 15.0 million shares were issuable under outstanding warrants and 9.46 million under options; the royalty financing could add warrants for up to 7.0 million more shares if supplemental funding is drawn. The company reported 100.58 million shares outstanding as of March 27, 2024.
- A March 2023 business-email-compromise fraud diverted approximately $0.4 million; about $0.2 million was covered by insurance. Daré reported no material impact. No material pending legal proceedings were disclosed.
- The 2023 financial statements received an unmodified audit opinion; the auditor identified no critical audit matters. Management reported effective disclosure controls and internal control over financial reporting, but no auditor attestation on internal controls was required for this non-accelerated filer.
Important facts for investors to verify
- Current unrestricted cash, spending runway, financing progress and the company’s ability to meet obligations after the stated Q3 2024 funding horizon.
- Ovaprene Phase 3 enrollment, supply readiness, timeline and eventual pregnancy-rate and safety results; whether Bayer elects to activate its license.
- FDA feedback on Sildenafil Cream’s Phase 3 endpoints, required safety database and remaining development costs, keeping in view that RESPOND missed its primary and secondary endpoints.
- Organon’s XACIATO sales, royalty reporting and the resulting cash available to Daré after licensor payments and the royalty-financing remittances.
- Compliance with Nasdaq’s exception conditions and any reverse-split action, as well as actual and potential dilution from warrants, options, equity offerings and supplemental royalty-financing draws.